Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Multiple-Dose Study to Evaluate the Safety and Tolerability of XmAb®23104 in Subjects With Selected Advanced Solid Tumors

NCT03752398 is registered in ClinicalTrials.gov with Xencor, Inc. as lead sponsor.

NCT NCT03752398
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03752398 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Multiple-Dose Study to Evaluate the Safety and Tolerability of XmAb®23104 in Subjects With Selected Advanced Solid Tumors
Lead sponsor
Xencor, Inc.
Phase
Phase 1
Overall status
Completed
Start date
May 1, 2019
Completion date
February 15, 2024
Enrollment
198 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors, breast carcinoma that is estrogen receptor, progesterone receptor, and her2 negative, cervical carcinoma, colorectal carcinoma, endometrial carcinoma, gastric or gastroesophageal junction adenocarcinoma, hepatocellular carcinoma, melanoma (excluding uveal melanoma), nasopharyngeal carcinoma, non-small cell lung carcinoma, pancreatic carcinoma, renal cell carcinoma, small cell lung cancer, squamous cell carcinoma of the head and neck, undifferentiated pleomorphic sarcoma, urothelial carcinoma